Hepatitis C virus-induced changes in microRNA 107 (miRNA-107) and miRNA-449a modulate CCL2 by targeting the interleukin-6 receptor complex in hepatitis

Nayan J. Sarma  
Washington University School of Medicine in St. Louis

Venkataswarup Tiriveedhi  
Washington University School of Medicine in St. Louis

Jeffrey S. Crippin  
Washington University School of Medicine in St. Louis

William C. Chapman  
Washington University School of Medicine in St. Louis

Thalachallour Mohanakumar  
Washington University School of Medicine in St. Louis

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Please let us know how this document benefits you.

Recommended Citation
Sarma, Nayan J.; Tiriveedhi, Venkataswarup; Crippin, Jeffrey S.; Chapman, William C.; and Mohanakumar, Thalachallour, "Hepatitis C virus-induced changes in microRNA 107 (miRNA-107) and miRNA-449a modulate CCL2 by targeting the interleukin-6 receptor complex in hepatitis." Journal of Virology. 88, 7. 3733-3743. (2014).  
https://digitalcommons.wustl.edu/open_access_pubs/2696

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact vanam@wustl.edu.
Hepatitis C Virus-Induced Changes in MicroRNA 107 (miRNA-107) and miRNA-449a Modulate CCL2 by Targeting the Interleukin-6 Receptor Complex in Hepatitis

Nayan J. Sarma, Venkataswarup Tiriveedhi, Jeffrey S. Crippin, William C. Chapman and Thalachallour Mohanakumar

Hepatitis C Virus-Induced Changes in MicroRNA 107 (miRNA-107) and miRNA-449a Modulate CCL2 by Targeting the Interleukin-6 Receptor Complex in Hepatitis

Nayan J. Sarma,a Venkataswarup Tiriveedhi,a Jeffrey S. Crippin,c William C. Chapman,a Thalachallour Mohanakumarab
Departments of Surgery,a Pathology and Immunology,c and Medicine,c Washington University School of Medicine, Saint Louis, Missouri, USA

ABSTRACT
Hepatitis C virus (HCV)-mediated liver diseases are one of the major health issues in the United States and worldwide. HCV infection has been reported to modulate microRNAs (miRNAs) that control various cell surface receptors and gene-regulatory complexes involved in hepatic inflammation and liver diseases. We report here that specific downregulation of miRNA-107 and miRNA-449a following HCV infection in patients with HCV-mediated liver diseases modulates expression of CCL2, an inflammatory chemokine upregulated in patients with chronic liver diseases, by targeting components of the interleukin-6 receptor (IL-6R) complex. Computational analysis for DNA-bound transcription factors in the CCL2 promoter identified adjacent binding sites for CCAAT/CEBPα, spleen focus-forming virus, proviral integration oncogene (SPI1/PU.1), and STAT3. We demonstrate that CEBPα, PU.1, and STAT3 interacted with each other physically to cooperatively bind to the promoter and activate CCL2 expression. Analysis of IL-6R and JAK1 expression in HCV patients by quantitative PCR showed significant upregulation when there was impaired miRNA-107 and miRNA-449a expression, along with upregulation of PU.1 and STAT3, but not CEBPα. miRNA-449a and miRNA-107 target expression of IL-6R and JAK1, respectively, in vitro and also inhibit IL-6 signaling and impair STAT3 activation in human hepatocytes. Taken together, our results demonstrate a novel gene-regulatory mechanism in which HCV-induced changes in miRNAs (miRNA-449a and miRNA-107) regulate CCL2 expression by activation of the IL-6-mediated signaling cascade, which we propose will result in HCV-mediated induction of inflammatory responses and fibrosis.

IMPORTANCE
Hepatitis C virus (HCV)-induced hepatitis is a major health concern worldwide. HCV infection results in modulation of noncoding microRNAs affecting major cellular pathways, including inflammatory responses. In this study, we have identified a microRNA-regulated pathway for the chemokine CCL2 in HCV-induced hepatitis. Understanding microRNA-mediated transcriptional-regulatory pathways will result in development of noninvasive biomarkers for better disease prediction and development of effective therapeutics.
In recent years, miRNAs have been shown to play an important role in immune evasion, allograft rejection, cell cycle regulation, and cancer progression (19–21). HCV infection has been shown to result in aberrant miRNA expression that regulates HCV particle entry, propagation, and gene expression mechanisms, thus playing a pivotal role in host immune evasion and inflammatory responses (22, 23). In this report, we demonstrate that HCV-mediated regulation of miRNA-449a and miRNA-107 results in upregulation of CCL2 and modulates components of the IL-6R complex, which we propose will result in HCV-mediated induction of inflammatory responses and fibrosis.

MATERIALS AND METHODS

Patients. Liver biopsy specimens were obtained from 10 healthy-donor livers (control), 10 alcoholic-hepatitis patients, 10 NASH patients, and 10 chronic-HCV patients (see Table S1 in the supplemental material). Patients with HIV and/or hepatitis B virus infection were not included in this study. The collection of human samples and the studies were approved by the Human Research Protection Committee at Washington University (protocol 201104075), and the patients were enrolled after obtaining written informed consent.

Plasmids and siRNA constructs. For the reporter constructs, the CCL2 promoter regions were amplified from human genomic DNA (Zyagen, CA) by PCR using iProof High-Fidelity DNA Polymerase (Bio-Rad, CA). The PCR products were subcloned into the pGL4.11 vector (Promega, WI) upstream of a luciferase gene using the KpnI/EcoRV restriction sites. Mutation in the STAT3 binding site in the base pair (bp) −300 promoter construct was carried out using PCR. pcMV-XL4-PU.1 (SC135715) and pcMV-XL4-STAT3 (SC124165), Hsa-miRNA-449a (SC400399), Hsa-miRNA-107 (SC400023), and controls were obtained from Origene, MD. The construction of pcDNA-CEBPα (SC315715) and pCMV-XL4-STAT3 (SC124165), Hsa-miRNA-449a (SC400399), Hsa-miRNA-107 (SC400023), and controls were obtained from Origene, MD. The construction of pcDNA-CEBPα is described elsewhere (23). Small interfering RNAs (siRNAs) specific for PU.1 (sc-36330), STAT3 (sc-29493), CEBPα (sc-37047), IL-6R (sc-35663), JAK1 (sc-35719), and a control (sc-37007) were purchased from Santa Cruz Bio-technology, CA. 3′-untranslated-region (UTR) clones of IL-6R (HmiT009673-MT01) and JAK1 (HmiT009849-MT01) were purchased from Genecopoeia, MD. Computational analysis to identify promoter-binding transcription factors was done using the Transcription Element Search System (TESS) (http://www.cbil.upenn.edu/cgi-bin/tess/tess). miRNA target gene analysis was done using the website http://www.targetscan.org.

miRNA and mRNA expression analysis. Total RNA was isolated from the human hepatocytes or liver biopsy specimens using the RNA aqueous kit (Ambion, NY). miRNA-449a and miRNA-107 levels were determined with the human hepatocytes or liver biopsy specimens using the qPCR. Specific downregulation of miRNA-107 and miRNA-449a, in HCV patients (23,25). To determine the role of IL-6 in CCL2 expression, biopsy specimens were collected from 10 normal livers from cadaveric donors, 10 alcoholic-hepatitis patients, 10 NASH patients, and 10 chronic-HCV patients. Expression analysis using qPCR demonstrated that miRNA-107 is specifically downregulated by more than 2-fold (2.2-fold) in HCV-infected patients (Fig. 1A). In contrast, no significant difference in the expression of miRNA-107 was observed in alcoholic-hepatitis, NASH, and normal livers. Similar, expression of miRNA-449a was also found to be specifically downregulated more than 2-fold (2.8-fold) only in the HCV-infected patients, but not in other disease conditions (Fig. 1B). RNU6B was used as the internal control.

Expression analysis showed upregulation of CCL2 in alcoholic hepatitis (6.2-fold), NASH (5.8-fold), and HCV (10.0-fold) compared to normal livers (Fig. 1C). Expression of CCL2 in HCV livers was significantly higher than in those of patients with alcoholic hepatitis and NASH (P < 0.001).

IL-6 regulates CCL2 activation through the IL-6R complex. Components of the IL-6R complex were shown to be essential for CCL2 expression (10). To determine the role of IL-6 in CCL2 expression, the reporter construct containing the –2,000-bp re-
gion of the human CCL2 promoter was transfected into human hepatocytes and treated or not with IL-6, and luciferase activity was measured. More than a 4-fold (4.7-fold) increase in the CCL2 reporter activity was observed in IL-6-treated cells compared to the untreated cells, which was further confirmed by immunoblotting (Fig. 2A). This strongly suggests that IL-6 activates CCL2 through modulation of upstream transcription factors. Further, knockdown of the IL-6 cell surface receptor gene, IL-6R, resulted in a 2-fold decrease in IL-6-mediated CCL2 activation and protein expression compared to controls (Fig. 2A). Knockdown of JAK1 also resulted in significant impairment (1.8-fold) of IL-6-mediated CCL2 reporter activity and protein expression (Fig. 2B). Quantitative gene expression analysis showed 88% and 86% knockdown of IL-6R and JAK1, respectively, in siRNA-treated cells (see Fig. S1 in the supplemental material).

Identification of putative DNA binding transcription factors in the CCL2 promoter regions. To identify DNA binding transcription factors that regulate the expression of CCL2, a computational analysis of −2,000 bp of the promoter region was performed using TESS. This bioinformatics analysis identified two putative DNA binding sites for CEBPβ (GCAAT), four sites for PU.1 (GAGGAA), and one site for STAT3 (TTCCTG GAA) at the bp −138 position (Fig. 3A) in close proximity to each other, suggesting that these three transcription factors may be part of a transcriptional-regulatory complex that mediates CCL2 expression.

To demonstrate that these transcription factors regulate CCL2 expression, human hepatocytes were transfected with the CCL2 reporter construct, along with either empty vector or vector expressing PU.1, STAT3, or CEBPα, and treated with IL-6 (Fig. 3B). A significant increase in reporter activity was observed compared to the empty vector with overexpression of PU.1 (3.3-fold), STAT3 (7.0-fold), and CEBPα (5.4-fold) (Fig. 3B). To determine whether these transcription factors cooperate in activating CCL2, two of the transcription factors (PU.1/STAT3, PU.1/CEBPα, or STAT3/CEBPα) were cotransfected into hepatocytes, along with the CCL2 reporter construct. Cotransfection resulted in a significant increase in reporter activity compared to either factor alone, suggesting cooperation between the factors in regulating CCL2 expression (Fig. 3B, top). Overexpression of the transcription factors in the hepatocytes was confirmed by immunoblotting (Fig. 3B).

To further demonstrate that these transcription factors are required for IL-6-mediated expression of CCL2, human hepatocytes were transfected with the CCL2 reporter construct, along with either control siRNAs or siRNAs specific for PU.1, STAT3, or CEBPα, and treated with IL-6. Knockdown of PU.1 resulted in 28%, that of STAT3 resulted in 37%, and that of CEBPα resulted in 25% decrease in the CCL2 reporter activity compared to the control (Fig. 3C). Knockdown of any two transcription factors (PU.1/STAT3, PU.1/CEBPα, or STAT3/CEBPα) resulted in a significant decrease in reporter activity compared to knockdown of either factor alone, suggesting cooperation between these factors in the transcriptional activation of CCL2 (Fig. 3C). Quantitative gene expression analysis showed 77%, 73%, and 75% knockdown of PU.1, STAT3, and CEBPα in siRNA-treated cells (see Fig. S1 in the supplemental material). However, coexpression or coknockdown of PU.1, STAT3, and CEBPα together impaired cell viability.

To determine whether the transcription factor binding sites are essential, deletion mutants were designed based on the locations of the DNA binding sites for CEBPα, PU.1, and STAT3 on the CCL2 promoter. These deletion mutants (Fig. 3D, black bars) were introduced into hepatocytes, treated or not with IL-6, and the luciferase activity was measured. Sequential deletion of the CCL2 promoter impaired IL-6-mediated transcriptional induction compared to the bp −2000 promoter (Fig. 3D). No signifi-
CCL2 promoter regions, demonstrating the specificity for these binding pattern of CEBP/H9251 locations of the consensus binding sites on the binding sites within STAT3 binds strongly to the CEBP/H9251/H11002/800 region of the H11002 complex and bind to the CCL2 promoter. specific for PU.1, anti-STAT3, or control IgGs. ChIP and PCR using primers CEBP/H9251, PU.1, and STAT3 bind to adjacent DNA binding sites on the CCL2 promoter. DNA-protein complexes from IL-6 treated hepatocytes were immunoprecipitated with anti-CEBP/H9251, anti-PU.1, anti-STAT3, or control IgGs. ChIP and PCR using primers specific for CCL2 promoter regions (Fig. 4A, black bars) demonstrated that CEBPα, PU.1, and STAT3 bind to the promoter (Fig. 4B). CEBPα binds strongly to the −800/−1200 and −400/−800 regions and weakly to the −1/−400 region; PU.1 binds strongly to the −800/−1200 and −1/−400 regions and weakly to the −400/−800 region of the CCL2 promoter. The observed binding of CEBPα in the −800/−1200 region is likely due to the presence of binding sites within ±250 bp of the PCR amplicon. The DNA binding pattern of CEBPα and PU.1 strongly correlates with the locations of the consensus binding sites on the CCL2 promoter. STAT3 binds strongly to the −1/−400 region, encompassing the binding site (bp −138). ChIP with the control IgGs did not enrich CCL2 promoter regions, demonstrating the specificity for these transcription factors. No binding was observed in PCRs carried out with primers specific for the −300/−700 region of the ACTIN (ACTA1) promoter that lacks these binding sites (Fig. 4B).

To further define the interaction between CEBPα, PU.1, and STAT3, HEPG2 cells were treated with IL-6 and coimmunostained with anti-STAT3/anti-CEBPα, anti-PU.1/anti-STAT3, or anti-PU.1/anti-CEBPα. All three transcription factors primarily colocalized to the nucleus (Fig. 4E; for high-resolution images and controls, see Fig. S2 and S3 in the supplemental material). The nuclear colocalization of STAT3 with CEBPα (Fig. 4E, top), PU.1

FIG 2 IL-6 regulates CCL2 activation through the IL-6 receptor complex components IL-6R and JAK1. (A) (Top) Hepatocytes were transfected with a reporter construct driven by −2,000 bp of the CCL2 promoter with (+) or without (−) IL-6 and nonspecific (control) siRNA or siRNAs specific for IL-6R. Firefly luciferase activity in the cells was measured 48 h after transfection and normalized to a Renilla luciferase internal control. The numbers represent the fold change over the untreated control (average of three independent replicates); the error bars represent SD. *, P < 0.05; two-tailed t test. (Bottom) The hepatocytes were immunoblotted with anti-CCL2. Actin was used as the loading control. (B) (Top) Hepatocytes were transfected with the CCL2 reporter construct with either nonspecific (control) siRNA or siRNAs specific for JAK1. The cells were treated with IL-6, and luciferase activity was measured as described for panel A. (Bottom) The hepatocytes were immunoblotted with anti-CCL2 and anti-actin.
with STAT3 (4E, middle), and PU.1 with CEBP/H9251 (4E, bottom) and coimmunoprecipitation (Fig. 4D) demonstrate that these transcription factors physically interact and are part of a larger transcription-regulatory complex.

miRNA-449a and miRNA-107 regulate IL-6-mediated CCL2 expression and STAT3 phosphorylation by targeting IL-6R and JAK1. To define the role of STAT3 in IL-6-mediated CCL2 expression, IL-6R or JAK1 knockout hepatocytes were treated or not with STAT3 (4E, middle), and PU.1 with CEBP/H9251 (4E, bottom) and coimmunoprecipitation (Fig. 4D) demonstrate that these transcription factors physically interact and are part of a larger transcription-regulatory complex.

FIG 3 Transcription factors CEBPα, PU.1, and STAT3 cooperate to regulate CCL2 expression. (A) Schematic representation of transcription factor binding sites in the CCL2 promoter identified by computational analysis of ~2,000 bp upstream of the open reading frame using TESS. The vertical bars represent the predicted consensus binding sites in the DNA for transcription factors CEBPα, PU.1, and STAT3. (B) (Top) Hepatocytes were transfected with the ~2,000-bp CCL2 promoter-driven luciferase construct, in addition to a control vector or vectors expressing CEBPα, PU.1, and STAT3 or any two of these factors. Luciferase activity was measured as described for Fig. 2A. (Bottom) Overexpression of CEBPα, PU.1, or STAT3 was verified by immunoblotting with anti-CEBPα, anti-PU.1, or anti-STAT3. (C) Hepatocytes were transfected with the CCL2 promoter-driven luciferase construct, in addition to either nonspecific (control) siRNA or siRNAs specific for CEBPα, PU.1, STAT3, or any two of these factors. Luciferase activity was measured as described for Fig. 2A. *, P value obtained by a two-tailed t test between the control and the individual transcription factors; **, P value between cotransfected transcription factors and either factor alone. (D) Essential regions in the CCL2 promoter required for IL-6-mediated expression. Hepatocytes were transfected with luciferase reporters driven by deletion constructs of CCL2 promoter constructs (bp −2000, −8000, −300, or −300 with STAT3 binding site mutated [*]) (black bars) with (+) or without (−) IL-6. Luciferase activity was measured as described for Fig. 2A. *, P value obtained by a two-tailed t test between conditions with or without IL-6.

MicroRNA-Mediated Changes in HCV-Induced Inflammation

April 2014 Volume 88 Number 7 jvi.asm.org

on April 21, 2014 by Washington University in St. Louis
FIG 4 CEBPα, PU.1, and STAT3 interact to bind to the CCL2 promoter. (A) Schematic representation of the CCL2 promoter showing binding sites for CEBPα, PU.1, and STAT3. The black horizontal bars represent regions specific for the PCR primers. (B) ChIP showing transcription factors binding to the CCL2 promoter. DNA-protein complexes were immunoprecipitated with anti-CEBPα, anti-PU.1, anti-STAT3, or isotype control IgG from hepatocytes. Specific CCL2 promoter regions (shown in panel A) were detected by PCR. The top four rows (CEBPα, PU.1, STAT3, IgG) represent immunoprecipitated chromatin, and the bottom row represents total chromatin (Input). ACTIN promoter amplification is shown as the negative control. (C) STAT3 is required for PU.1 binding to the CCL2 promoter. Hepatocytes were transfected with either nonspecific (control) siRNA or siRNAs specific for STAT3. DNA-protein complexes were immunoprecipitated with anti-PU.1. The top row represents CCL2 promoter regions immunoprecipitated by anti-PU.1 in hepatocytes transfected with nonspecific siRNA, the middle row represents hepatocytes transfected with siRNAs specific for STAT3, and the bottom row shows input chromatin (Input). (D) Coimmunoprecipitation showing interaction between CEBPα, PU.1, and STAT3 in hepatocytes. Whole-cell lysates (Input) from IL-6-treated hepatocytes were subjected to immunoprecipitation with either isotype control IgG, anti-CEBPα, or anti-STAT3, and the immunoprecipitated complexes (IP) were detected by immunoblotting with anti-PU.1 or anti-STAT3. (E) Nuclear colocalization of CEBPα, PU.1, and STAT3. HEPG2 cells were treated with IL-6 and coimmunostained with anti-STAT3/anti-CEBPα (top row), anti-PU.1/anti-STAT3 (middle row), or anti PU.1/anti-CEBPα (bottom row).
with IL-6 and subjected to immunoblotting using anti-pSTAT3, which is specific for the phosphorylated form of STAT3. IL-6 treatment resulted in increased accumulation of phosphorylated STAT3, and knockdown of IL-6R and JAK1 resulted in impairment of IL-6-mediated STAT3 phosphorylation (Fig. 5A).

To test whether HCV-mediated upregulation of CCL2 is regulated by miRNAs, human hepatocytes were transfected with the CCL2 reporter construct, along with a control vector or vector expressing miRNA-449a and/or miRNA-107, and treated or not with IL-6. Expression of either miRNA-449a or miRNA-107 resulted in significant impairment (>2.5-fold) of IL-6-mediated expression of CCL2 (Fig. 5B). Expression of both miRNA-449a and miRNA-107 resulted in further impairment (6.1-fold) of CCL2 activation compared to either miRNA alone, indicating cooperation between the two miRNAs (Fig. 5C). Expression of either of these miRNAs also resulted in decreased CCL2 protein and STAT3 phosphorylation (Fig. 5C), which was further accentuated by expression of both miRNAs together, indicating cooperation in mediating transcriptional signaling (Fig. 5D).

Computational target prediction of miRNA-449a and miRNA-107 using Targetscan identified the 3'-UTR regions of IL-6R or JAK1, along with either control vector or vector expressing miRNA-449a or miRNA-107, and luciferase activity was measured. Expression of miRNA-449a and miRNA-107 resulted in significant reduction in the IL-6R (3.8-fold) and JAK1 (3-fold) UTR reporter activity, indicating direct interaction between the miRNAs and the 3'-UTR regions (Fig. 6B and F). To further demonstrate that these miRNAs impair gene expression, hepatocytes were transfected with either control vector or vector expressing miRNA-449a or miRNA-107, and expression of IL-6R and/or JAK1 was determined by qPCR and immunoblotting. Increased expression of miRNA-449a or miRNA-107 resulted in more than 2-fold downregulation of IL-6R (55%) and JAK1 (67%) RNA and protein levels (Fig. 6C, D, G, and H).

**IL-6R, JAK1, PU.1, and STAT3 are upregulated in HCV patients.** To determine whether downregulation of miRNA-449a and miRNA-107 in HCV livers is accompanied by upregulation of their respective targets, IL-6R and JAK1, RNA was isolated from 10 normal, 10 alcoholic-hepatitis, 10 NASH, and 10 chronic-HCV livers. qPCR analysis showed that IL-6R and JAK1 were upregulated more than 2-fold (2.7- and 2.2-fold, respectively) in HCV livers (Fig. 7A and B). In contrast, no significant difference in the expression of IL-6R and JAK1 was noted in alcoholic-hepatitis, NASH, and normal livers. These results, along with our results from in vitro studies using human hepatocytes, clearly indicate...
that upregulation of \(IL-6R\), \(JAK1\), and \(CCL2\) (Fig. 1C) in HCV livers can be attributed to downregulation of miRNA-449a and miRNA-107.

Expression analysis of the transcription factors also showed that \(PU.1\) is upregulated (3.6-fold) only in HCV livers compared to non-HCV and normal livers (Fig. 7C). However, expression of \(STAT3\) is upregulated 2.4-fold in alcoholic-hepatitis patients, 3.1-fold in NASH patients, and 6.6-fold in HCV livers compared to normal livers (Fig. 7D). We did not detect any differences in the expression of CEBPs in any of these patient populations (Fig. 7E).

\(GAPDH\) was used as the internal control.

**DISCUSSION**

HCV infection has been shown to induce inflammatory cytokines/chemokines, leading to activation of hepatic stellate cells (HSCs) and development of fibrosis (26). We have previously identified differential regulation of inflammatory cytokines, such as IL-17, IL-1\(\beta\), IL-6, IL-8, monocyte chemoattractant protein 1 (MCP-1), gamma interferon (IFN-\(\gamma\)), IL-4, IL-5, IL-10, and YKL40 in HCV patients with fibrosis (23, 27). In this study, we demonstrate that HCV-mediated specific regulation of miRNA-449a and miRNA-107 alters expression of CCL2, a major inflammatory chemokine that is regulated by the IL-6R complex components \(IL-6R\) and \(JAK1\). It is known that CCL2 is expressed in the HSCs, regulates HSC chemotaxis to the site of injury, and promotes HCV-induced hepatic fibrosis (28–30). Increased expression of CCL2 is associated with chronic HCV infection, and IFN-\(\alpha\) therapy has been shown to reduce its expression (9). Further, inhibition of CCL2 results in reduced cellular infiltration, steatohepatitis, inflammatory responses, and fibrosis during liver injury (31, 32). IL-6 has also been shown to be upregulated in HCV patients through NSSA-mediated induction of Toll-like receptor 4 (TLR4) (33), and IL-6 can induce CCL2, leading to increased inflammatory responses (34). The results presented in this report indicate that HCV-induced induction of IL-6 can also lead to induction of CCL2, resulting in HSC chemotaxis and hepatic fibrosis (Fig. 2).

Transcription factors play a significant role in regulating inflammatory responses, development of fibrosis, and HCC. Our results demonstrate that CEBPs, \(PU.1\), and \(STAT3\) form a functional transcriptional-activation complex to regulate CCL2 ex-
pression in hepatocytes (Fig. 3 and 4). CEBPα has been shown to regulate HSC activation, which plays a major role in hepatic fibrosis (35, 36). PU.1 knockout mice lack neutrophils, macrophages, and mast cells and do not elicit inflammatory responses or fibrosis (37). Both CEBPα and PU.1 bind and cooperate to activate expression of myeloid-specific genes, such as murine neutrophil elastase promoter and granulocyte colony-stimulating factor (G-CSF) receptor, which is necessary for neutrophil differentiation (38, 39). Further, STAT3 binding to the PU.1 promoter is required for its expression and subsequent hematological differentiation (40). STAT3 has also been shown to bind to the promoter and activate CCL2 expression in rat smooth muscle cells (41). Activated STAT3 is a proviral host factor and is required for HCV replication (42). Therefore, the CEBPα-PU.1-STAT3 transcription-regulatory complex plays a significant role in cellular differentiation, inflammatory gene expression, and development of hepatic fibrosis.

miRNAs are regulators of HCV infection, fibrosis, cirrhosis, and development of HCC following liver transplantation (21, 43). miRNAs regulate cytokine signaling on HSCs and expression of inflammatory cytokines and interferons, leading to fibrosis (44, 45). We have shown that miRNA-449a and miRNA-107 are specifically downregulated in HCV patients (Fig. 1A and B) and that miRNA-449a regulates expression of the inflammatory cytokine YKL40 through components of the NOTCH signaling pathway (23). miRNA-125b and miRNA-124, which are downregulated in hepatocarcinoma patients, target IL-6R to modulate the IL-6/STAT3 pathway and IL-6 production and induce tumorigenicity (46–48). We demonstrate that expression of miRNA targets IL-6R and JAK1 and that transcription factors PU.1 and STAT3 are upregulated specifically in HCV patients compared to non-HCV patients and healthy individuals (Fig. 7). Although STAT3 was upregulated in alcoholic-hepatitis and NASH patients compared to healthy donors, the expression was 2-fold higher in HCV patients. We propose that in cases of HCV infection, the viral protein NS5A or the core protein may increase its expression and promote phosphorylation and nuclear translocation of STAT3 (49, 50). Therefore, HCV-induced downregulation of miRNA-449a and miRNA-107 in human livers can activate transcriptional-regulatory complexes (CEBPα-PU.1-STAT3) through modulation of

**FIG 7** IL-6R, JAK1, PU.1, and STAT3 are upregulated in HCV patients. Total RNA was isolated from liver biopsy specimens obtained from 10 chronic-HCV patients, 10 alcoholic-hepatitis patients, 10 NASH patients, and 10 healthy-donor livers (control). Expression levels of IL-6R (A), JAK1 (B), PU.1 (C), STAT3, and CEBPα (E) were determined by qPCR. The ΔΔCt values were calculated by normalizing the Ct values with GAPDH expression and IL-6R, JAK1, PU.1, STAT3, and CEBPα expression in controls. *p < 0.05; two-tailed t test. The error bars represent SD.
cell surface receptor (IL-6R/JAK1) expression, thereby promoting inflammatory responses that lead to development of fibrosis and HCC. (Fig. 8). Since we and others have found that CCL2 is also elevated in patients with alcoholic hepatitis and NASH (Fig. 1C) (7–9), although significantly lower than in HCV infection, it is possible that parallel gene-regulatory mechanisms may operate in non-HCV-mediated liver diseases.

Taken together, the results of this study provide novel insights into the miRNA-mediated gene regulation mechanisms that play a role in HCV-mediated inflammatory responses and development of liver fibrosis. The HCV-specific modulation of miRNA, transcription factors, and cell surface receptors identified in this report can be utilized for the potential development of noninvasive biomarkers that can identify HCV patients with higher risk for developing fibrosis, cirrhosis, and HCC, as well as in developing methods for altering miRNA expression levels (miRNA mimics or antagonists) as a therapeutic strategy.

ACKNOWLEDGMENTS
This work was supported by NIH DK065982 and the Barnes-Jewish Foundation (T.M.). We thank Billie Glasscock for her help in preparing the manuscript. We have no financial conflicts of interest.

REFERENCES


